- Home
- EXK vs KNSA Comparison
EXK vs KNSA Comparison
Compare EXK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXK | KNSA |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EXK | KNSA |
|---|---|---|
| Price | $10.05 | $42.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $11.69 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 16.0M | 376.3K |
| Earning Date | 11-07-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $337,137,000.00 | ★ $597,973,000.00 |
| Revenue This Year | $111.57 | $62.63 |
| Revenue Next Year | $64.09 | $29.93 |
| P/E Ratio | ★ N/A | $89.97 |
| Revenue Growth | 49.22 | ★ 55.68 |
| 52 Week Low | $2.95 | $17.82 |
| 52 Week High | $10.37 | $44.42 |
Technical Indicators
Market Signals| Indicator | EXK | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 54.82 |
| Support Level | $9.52 | $40.77 |
| Resistance Level | $10.22 | $44.42 |
| Average True Range (ATR) | 0.58 | 1.28 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 87.63 | 47.14 |
Price Performance
Historical ComparisonAbout EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.